Table 4.
Vaccine effectiveness against COVID-19-related ICU admission and death by vaccine type and duration since full vaccination
|
‘Late’ (Fully Vaccinated in July to August) |
‘Early’ (Fully Vaccinated in April to June) |
||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total | Event | per 1,000 | VE | CI (95%) | Total | Event | per 1,000 | VE | CI (95%) | ||||
| Age Group (in years) | ICU Admission | ||||||||||||
| Overall | Unvaccinated | 62,506 | 1,238 | 20 | ref | ref | 62,506 | 1,238 | 20 | ref | ref | ||
| BNT162b2 | 30,088 | 101 | 3 | 86.0 | (82.8, 88.6) | 21,906 | 91 | 4 | 77.5 | (71.7, 82.1) | |||
| CoronaVac | 104,746 | 830 | 8 | 56.0 | (51.2, 60.2) | 6,052 | 110 | 18 | 28.7 | (12.2, 42.1) | |||
| 18–39 | Unvaccinated | 39,846 | 267 | 7 | ref | ref | 39,846 | 267 | 7 | ref | ref | ||
| BNT162b2 | 12,598 | 6 | 0 | 94.9 | (88.3, 97.7) | 11,784 | 7 | 1 | 92.3 | (82.6, 96.6) | |||
| CoronaVac | 52,174 | 64 | 1 | 81.9 | (75.1, 86.8) | 2,197 | 11 | 5 | 43.5 | (-5.1, 69.6) | |||
| 40–59 | Unvaccinated | 14,998 | 536 | 36 | ref | ref | 14,998 | 536 | 36 | ref | ref | ||
| BNT162b2 | 9,440 | 37 | 4 | 90.2 | (86.2, 93.0) | 6,616 | 22 | 3 | 89.9 | (83.3, 93.9) | |||
| CoronaVac | 34,904 | 323 | 9 | 71.2 | (66.1, 75.5) | 1,771 | 34 | 19 | 38.3 | (10.9, 57.2) | |||
| ≥60 | Unvaccinated | 7,662 | 435 | 57 | ref | ref | 7,662 | 435 | 57 | ref | ref | ||
| BNT162b2 | 8,050 | 58 | 7 | 83.8 | (78.5, 87.8) | 3,506 | 62 | 18 | 57.1 | (43.2, 67.6) | |||
| CoronaVac | 17,668 | 443 | 25 | 46.1 | (37.1, 53.8) | 2,084 | 65 | 31 | 30.3 | (7.7, 47.4) | |||
| Age Group (in years) | Death | ||||||||||||
| Overall | Unvaccinated | 62,506 | 2,550 | 41 | ref | ref | 62,506 | 2,550 | 41 | ref | ref | ||
| BNT162b2 | 30,088 | 175 | 6 | 91.5 | (89.8, 92.9) | 21,906 | 98 | 4 | 91.2 | (88.6, 93.1) | |||
| CoronaVac | 104,746 | 762 | 7 | 79.2 | (76.8, 81.4) | 6,052 | 85 | 14 | 76.2 | (68.8, 81.9) | |||
| 18–39 | Unvaccinated | 39,846 | 243 | 6 | ref | ref | 39,846 | 243 | 6 | ref | ref | ||
| BNT162b2 | 12,598 | 4 | 0 | 94.3 | (84.3, 97.9) | 11,784 | 3 | 0 | 94.4 | (80.3, 98.4) | |||
| CoronaVac | 52,174 | 25 | 0 | 88.3 | (81.1, 92.7) | 2,197 | 4 | 2 | 59.5 | (-11.5, 85.3) | |||
| 40–59 | Unvaccinated | 14,998 | 740 | 49 | ref | ref | 14,998 | 740 | 49 | ref | ref | ||
| BNT162b2 | 9,440 | 28 | 3 | 94.5 | (91.7, 96.3) | 6,616 | 9 | 1 | 94.6 | (89.0, 97.4) | |||
| CoronaVac | 34,904 | 162 | 5 | 85.5 | (82.1, 88.3) | 1,771 | 8 | 5 | 82.6 | (63.6, 91.7) | |||
| ≥60 | Unvaccinated | 7,662 | 1,567 | 205 | ref | ref | 7,662 | 1,567 | 205 | ref | ref | ||
| BNT162b2 | 8,050 | 143 | 18 | 90.4 | (88.2, 92.3) | 3,506 | 86 | 25 | 89.4 | (86.0, 92.0) | |||
| CoronaVac | 17,668 | 575 | 33 | 76.3 | (72.7, 79.4) | 2,084 | 73 | 35 | 75.4 | (66.7, 81.9) | |||
Abbreviations: CI, confidence intervals; COVID-19, coronavirus disease; ICU, intensive care unit; VE, vaccine effectiveness; BNT162b2, Pfizer-BioNTech; CoronaVac, Sinovac.
The estimates were adjusted for age, gender, presence of comorbidities, nationality, and states of residence.
The analysis compares between the ‘Late’ group, individuals vaccinated in July–August 2021 (1–2 months after vaccination during the outcomes observation period in September 2021), and the ‘Early’ group, individuals vaccinated in April–June 2021 (3–5 months after vaccination), and unvaccinated individuals who act as the baseline